Methods: To demonstrate the antimicrobial activity of Provodine, the product was tested in suspension time-kill assays against Ebola Zaire-95, Marburg, Lassa and MERS coronavirus. Subsequently, skin surface killing was assessed using a pig skin model wherein the product was applied and then challenged with virus at specific time points after application. Finally, the activity of the product on bacterial and fungal pathogens was assessed in two separate in-vitro systems (artificial skin using MRSA, A. baumanii and C. albicans and mature biofilm using MRSA, VRE, A. baumanii, S. pyogenes, P. aeruginosa, H. influenza and C. albicans).
Results: Provodine demonstrated both short-term killing of virus (> 3 log reductions in 30 seconds), as well as prolonged killing (>90%) of newly introduced virus for at least 12 hours after product application in the pig skin model. In addition, Provodine was able to produce > 4 log reductions in freshly introduced bacterial and fungal CFU out to 9 hours after product application on artificial skin and > 4 log reductions in recoverable CFU when tested against mature biofilm. Finally, confocal microscopic imaging of punch biopsies from human skin (normal volunteer) demonstrates the selective deposition of PVP-I in the epidermis.
Conclusion: Provodine appears to be a superior professional antiseptic for use against both common pathogens, MDRO, and emerging pathogens of concern to the biodefense and infectious disease communities.
S. Bavari, None
J. Cheronis, Microdermis: Employee and Shareholder , Salary